Sarep­ta's sec­ond shot at show­ing its Duchenne gene ther­a­py de­liv­ers pos­i­tive da­ta but un­der­whelms — shares tum­ble

When Sarep­ta re­vealed last Jan­u­ary that its gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy had failed the key func­tion­al end­point in Part 1 of a Phase II tri­al, ex­ec­u­tives un­der­scored that there’s a sec­ond part to the study — giv­ing them an­oth­er shot at a fa­vor­able read­out.

One year lat­er, Sarep­ta is tak­ing the vir­tu­al podi­um at JP Mor­gan to present what they call pos­i­tive re­sults.

But re­ac­tions are de­cid­ed­ly mixed, and in­vestors sent shares $SRPT tum­bling 10.94% to $76.15.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER